Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders : High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemiaHONGHAO YANG; ROSOVE, M. H; FIGLIN, R. A et al.American journal of hematology. 1999, Vol 62, Num 4, pp 247-250, issn 0361-8609Article

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer : an outpatient multicenter trialVOGELZANG, N. J; LIPTON, A; FIGLIN, R. A et al.Journal of clinical oncology. 1993, Vol 11, Num 9, pp 1809-1816, issn 0732-183XArticle

Tumor necrosis factor: current clinical status and implications for nursing managementsMOLDAWER, N. P; FIGLIN, R. A.Seminars in oncology nursing. 1988, Vol 4, Num 2, pp 120-125, issn 0749-2081Article

Phase II trial of α-lymphoblastoid interferon given weekly as treatment of advanced breast cancerSARNA, G. P; FIGLIN, R. A.Cancer treatment reports. 1985, Vol 69, Num 5, pp 547-549, issn 0361-5960Article

Intracranial recurrence of carcinoma after complete surgical resection of stage I, II and III non-small-cell lung cancerFIGLIN, R. A; PIANTA DOSI, S; FELD, R et al.The New England journal of medicine. 1988, Vol 318, Num 20, pp 1300-1305, issn 0028-4793Article

Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complexHOFFMAN, D. M. J; FIGLIN, R. A.World journal of urology (Print). 2000, Vol 18, Num 2, pp 152-156, issn 0724-4983Article

Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumorFIGLIN, R. A; PIERCE, W. C; KABOO, R et al.The Journal of urology. 1997, Vol 158, Num 3, pp 740-745, issn 0022-5347, 1Article

Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinomaFIGLIN, R. A; PIERCE, W. C; BELLDEGRUN, A et al.Seminars in oncology. 1993, Vol 20, Num 6, pp 11-15, issn 0093-7754, SUP9Conference Paper

Treatment of renal cell carcinoma with α (human leukocyte) interferon and vinblastine in combination: a phase I-II trialFIGLIN, R. A; DE KERNION, J. B; MALDAZYS, J et al.Cancer treatment reports. 1985, Vol 69, Num 3, pp 263-267, issn 0361-5960Article

Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and Stage IV non-small cell lung cancerHASKELL, C. M; MENDOZA, E; PISTERS, K. M. W et al.Investigational new drugs. 1998, Vol 16, Num 1, pp 81-85, issn 0167-6997Article

Evaluation of cisplatin, carboplatin, an etoposide in metastatic nonsmall cell lung carcinoma : A phase II study of the Southwest Oncology GroupFIGLIN, R. A; CROWLEY, J. J; JACOBS, E. L et al.Cancer. 1996, Vol 78, Num 5, pp 998-1003, issn 0008-543XArticle

Immunotherapy and gene therapyGITLITZ, B. J; BELLDEGRUN, A; FIGLIN, R. A et al.Seminars in urologic oncology. 1996, Vol 14, Num 4, pp 237-243, issn 1081-0943Article

Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapyBELLDEGRUN, A; PIERCE, W; SAYAH, D et al.Journal of immunotherapy. 1993, Vol 13, Num 3, pp 175-180, issn 1053-8550Article

Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the functional living index-cancerGANZ, P. A; HASKELL, C. M; FIGLIN, R. A et al.Cancer. 1988, Vol 61, Num 4, pp 849-856, issn 0008-543XArticle

Selective decrease in Leu8-negative T cell subpopulations following treatment with recombinant interferon-α2a(rIFN-α2a)MARTINEZ-MAZA, O; FIGLIN, R. A; GIORGI, J. V et al.Cellular immunology (Print). 1988, Vol 117, Num 1, pp 89-98, issn 0008-8749Article

A phase 3 randomized trial of immediate combination chemotherapy vs delayed combination chemotherapy in patients with completely resected stabe II and III non-small cell carcinoma of the lungFIGLIN, R. A; PIANTODOSI, S.Chest. 1994, Vol 106, Num 6, pp 310S-312S, issn 0012-3692, SUPArticle

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-αPATIL, S; FIGLIN, R. A; HUTSON, T. E et al.British journal of cancer. 2012, Vol 106, Num 10, pp 1587-1590, issn 0007-0920, 4 p.Article

Prognostic indicators for renal cell carcinoma : A multivariate analysis of 643 patients using the revised 1997 TNM staging criteriaTSUI, K.-H; SHVARTS, O; SMITH, R. B et al.The Journal of urology. 2000, Vol 163, Num 4, pp 1090-1095, issn 0022-5347Article

Multicenter, randomized, phase III trial of CD8⁺ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinomaFIGLIN, R. A; THOMPSON, J. A; BUKOWSKI, R. M et al.Journal of clinical oncology. 1999, Vol 17, Num 8, pp 2521-2529, issn 0732-183XArticle

Cellular therapy : scientific rationale and clinical results in the treatment of metastatic renal-cell carcinomaPIERCE, W. C; BELLDEGRUN, A; FIGLIN, R. A et al.Seminars in oncology. 1995, Vol 22, Num 1, pp 74-80, issn 0093-7754Article

Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancerREISSMANN, P. T; KOGA, H; TAKAHASHI, R et al.Oncogene (Basingstoke). 1993, Vol 8, Num 7, pp 1913-1919, issn 0950-9232Article

Atypical contrast reactions associated with systemic interleukin-2 therapyFISHMAN, J. E; ABERLE, D. R; MOLDAWER, N. P et al.American journal of roentgenology (1976). 1991, Vol 156, Num 4, pp 833-834, issn 0361-803XArticle

Metastatic renal cell cancer : interleukin-2 toxicity induced by contrast agent injectionABI-AAD, A. S; FIGLIN, R. A; BELLDEGRUN, A et al.Journal of immunotherapy. 1991, Vol 10, Num 4, pp 292-295, issn 1053-8550Article

Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alphaJACOBS, E. L; CLARE-SALZLER, M. J; CHOPRA, I. J et al.Journal of immunotherapy. 1991, Vol 10, Num 6, pp 448-455, issn 1053-8550Article

Application of a new method for detecting the phenotype of target binding cellsLINDEMANN, R. A; JENKINS, J. A; FIGLIN, R. A et al.Cancer immunology and immunotherapy. 1987, Vol 25, Num 2, pp 153-155, issn 0340-7004Article